Halogenated retinoid derivatives as dual RARα and RXRα modulators for treating acute promyelocytic leukemia cells

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Acute promyelocytic leukemia (APL) is an AML subtype driven by the PML-RARα fusion protein.
• Retinoid X receptor α (RXRα) plays a key role in PML-RARα-driven tumorigenesis.
• Targeting both RARα and RXRα is a promising strategy for APL treatment.

Purpose of the Study:

• To develop novel dual RARα and RXRα targeting compounds for APL treatment.
• To investigate the structure-activity relationships of halogenated retinoids in APL.
• To identify potential drug candidates for both ATRA-sensitive and resistant APL.

Main Methods:

• Synthesis of brominated retinoid isomers (5a, 5b) with selective RARα and RXRα activity.
• Evaluation of compounds 5a and 5b in APL cells at varying concentrations.
• Modification of compound 5a by replacing bromine with chlorine (compound 7) or iodine (compound 8a).
• Assessment of the effects of halogenated compounds on PML-RARα degradation, differentiation, cell cycle arrest, and apoptosis.

Main Results:

• Compounds 5a and 5b effectively degrade PML-RARα and induce differentiation at low doses (RARα activation).
• Higher doses of 5a and 5b induce G2/M arrest and apoptosis in APL cells (RXRα activation).
• Chlorinated compound 7 primarily activates RXRα, inducing apoptosis.
• Iodinated compound 8a primarily activates RARα, inducing differentiation.
• Compounds demonstrate efficacy in both ATRA-sensitive and ATRA-resistant APL cells.

Conclusions:

• Halogen choice significantly influences RARα and RXRα activity in retinoid design.
• Compounds 5a, 5b, 7, and 8a represent promising therapeutic candidates for APL.
• The study highlights the utility of rational halogen modification for developing dual-targeting APL drugs.